Botswana Tenofovir Oral HIV Prophylaxis Trial

Phase 3TerminatedNCT00111150

Centers for Disease Control and Prevention1,200 enrolled

Overview

This study will test whether taking a pill of tenofovir (an antiretroviral medicine) is safe for sexually-active young adults in Botswana without HIV infection and whether it will reduce their risk of getting an HIV infection.

Twelve hundred healthy, sexually active women and men, 18-29 years old, without HIV infection will be enrolled in Francistown and Gaborone, Botswana. They will be provided with free male and female condoms, repeated individualized risk-reduction counseling, diagnosis and treatment of sexually transmitted diseases, and women will be provided with a choice of effective family planning methods. In addition, volunteers will be randomized to receive either Tenofovir or a placebo pill to take once a day. Volunteers will be seen monthly for at least 12 months to monitor for side effects and toxicities and to test their HIV status. Persons who become HIV infected during the trial will receive ongoing supportive counseling, CD4 and viral load monitoring, education about HIV infection/disease, and access to HIV care including free antiretrovirals when clinically indicated. Volunteer safety will be monitored by a local ethics committee, Centers for Disease Control Institutional Review Board (CDC IRB) and an independent data safety and monitoring board.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

1,200

Conditions

HIV Infection

Interventions

Tenofovir Disoproxil Fumarate 300 mg dailyDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 29 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * citizen of Botswana 18-29 years old * sexually active * HIV uninfected * Hepatitis B and C uninfected * Calculated creatinine clearance \>= 60 mL/min * hemoglobin \>= 8 gm/dL * ALT and AST \<= 2x ULN * total bilirubin \<= 1.5 mg/dL * total serum amylase \<= 1.5x ULN * Serum phosphorus \>= 2.2 mg/dL * willing to use effective contraception * living within 1 hours travel of study clinic * pass comprehension test * willing and able to give informed consent Exclusion Criteria: * history of significant renal or bone disease * any chronic illness requiring ongoing prescription medication * pregnant or breastfeeding * planning to move away from site in the next year * participating in another HIV prevention or vaccine safety trial * any other clinical condition or prior therapy that, in the opinion of the study physician, would make the volunteer unsuitable for the study or unable to comply with the dosing requirements

Locations (2)

Centers for Disease Control and Prevention

Atlanta, Georgia, United States

BOTUSA HIV Prevention Research Unit

Francistown and Gaborone, Botswana

Outcomes

Primary Outcomes

Adverse drug reactions in the tenofovir and placebo arms

HIV incidence in the tenofovir and placebo arms

Secondary Outcomes

Changes in levels of unprotected sex during the trial

Adherence to medication

Antiretroviral (ARV) resistance patterns in seroconverters

Viral set point in seroconverters

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.